Anakha J, Prasad Yenisetti Rajendra, Pande Abhay H
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India.
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India.
Vascul Pharmacol. 2025 Mar;158:107459. doi: 10.1016/j.vph.2024.107459. Epub 2024 Dec 19.
Angiogenesis plays a pivotal role in various pathological conditions, making it a key target in therapeutic development. Anti-angiogenic therapies are gaining traction for their potential in treating a range of angiogenesis-dependent diseases. Among these, endogenous angiogenesis inhibitors, particularly endostatin, have garnered significant attention for their therapeutic potential. While extensively studied for its anti-angiogenic effects in cancer, endostatin also exhibits anti-atherosclerotic and anti-fibrotic properties, broadening its therapeutic scope. Despite the successful clinical use of recombinant human endostatin in China for nearly two decades, its broader therapeutic potential remains underexplored. Thus, this review delves into the multifaceted applications of endostatin, examining its role in ocular diseases, inflammation, reproductive disorders, and tumor angiogenesis. Furthermore, it provides a comprehensive overview of its emerging roles beyond angiogenesis, particularly in the context of atherosclerosis and fibroproliferative conditions.
血管生成在各种病理状况中起着关键作用，使其成为治疗开发的关键靶点。抗血管生成疗法因其在治疗一系列血管生成依赖性疾病方面的潜力而越来越受到关注。其中，内源性血管生成抑制剂，特别是内皮抑素，因其治疗潜力而备受关注。虽然内皮抑素在癌症抗血管生成作用方面已得到广泛研究，但它也表现出抗动脉粥样硬化和抗纤维化特性，从而拓宽了其治疗范围。尽管重组人内皮抑素在中国成功临床应用近二十年，但其更广泛的治疗潜力仍未得到充分探索。因此，本综述深入探讨内皮抑素的多方面应用，研究其在眼部疾病、炎症、生殖系统疾病和肿瘤血管生成中的作用。此外，它还全面概述了内皮抑素在血管生成之外的新作用，特别是在动脉粥样硬化和纤维增生性疾病背景下的作用。
